Non-Small Cell Lung Cancer: From Screening to Treatment

Non-small cell lung cancer (NSCLC) is the most common form of lung cancer, accounting for roughly 80 to 85 percent of all cases. It is not a single disease but a group of cancers that share a common feature: the malignant cells are not the “small cell” type seen under a microscope. The three main subtypes are adenocarcinoma, squamous cell carcinoma, and large cell carcinoma, and each behaves differently, responds to different treatments, and tends to arise in different parts of the lung. Understanding what NSCLC is, who gets it, and how it is treated has changed dramatically over the past two decades, driven by molecular testing, immunotherapy, and earlier detection.

Who Gets It and Why

Smoking remains the dominant risk factor for lung cancer, but the picture is more complicated than “smokers get lung cancer.” Air pollution, occupational exposures like asbestos and radon, and genetic factors all play a role. A family history of lung cancer raises risk in both smokers and people who have never smoked.¹ Among never-smokers who develop NSCLC, the profile looks different: they tend to be younger, more often female, and more likely to have adenocarcinoma specifically. In one study, the overall five-year survival rate was higher in never-smokers (about 64 percent) than in smokers (about 56 percent), likely because their tumors carry different molecular drivers that respond well to targeted drugs.²

Certain inherited gene variants also raise risk substantially. Two recognized susceptibility syndromes exist, both linked to the adenocarcinoma subtype. Li-Fraumeni syndrome, caused by variants in the TP53 gene, predisposes carriers to a range of cancers including lung cancer. A separate syndrome involves inherited EGFR variants, particularly T790M, and appears to raise risk specifically for lung cancer. Emerging evidence suggests that variants in ATM and in genes related to surfactant proteins (SFTPA1 and SFTPA2) may independently increase risk as well.³ These hereditary pathways help explain why lung cancer sometimes appears in families with no significant smoking history.

Catching It Early With Low-Dose CT Screening

One of the biggest shifts in lung cancer outcomes has come from screening. Low-dose computed tomography (LDCT) scans can find tumors when they are still small and potentially curable. The landmark U.S. National Lung Screening Trial found that screening high-risk adults with LDCT, rather than conventional chest X-ray, reduced lung cancer deaths by about 20 percent.⁴ A European trial, known as NELSON, went further: comparing LDCT screening to no screening at all, it reported a 24 percent reduction in lung cancer deaths at ten years of follow-up.⁵

Current guidelines in the United States recommend annual LDCT screening for adults aged 50 to 80 who have a substantial smoking history, generally defined as 20 or more pack-years, and who currently smoke or quit within the past 15 years. The challenge remains getting eligible people to actually undergo screening: uptake is low in many countries, and implementing these programs at scale involves logistics, cost, and managing the false positives that inevitably come with scanning large populations.⁶

How Molecular Testing Changed Treatment

A generation ago, nearly all NSCLC patients received the same platinum-based chemotherapy. Today, one of the first things an oncologist does after a biopsy is send the tumor tissue for molecular testing. The goal is to find “actionable” mutations or gene rearrangements: specific changes in the tumor’s DNA that can be targeted with drugs designed to block those exact pathways.

EGFR mutations are among the most common actionable targets in NSCLC, especially in adenocarcinomas. Tyrosine kinase inhibitors (TKIs) that block the EGFR protein are the most widely used class of targeted therapy for this disease.⁷ First-line treatment for EGFR-positive NSCLC now includes options like osimertinib alone or combined with chemotherapy, or newer combinations such as amivantamab with lazertinib.⁸ These drugs have meaningfully extended survival compared to chemotherapy alone.

ALK and ROS1 gene rearrangements represent another set of targets. Crizotinib, the first drug developed for ALK-positive NSCLC, became the standard first-line treatment for that group and also received approval for ROS1-positive disease.⁹ Newer ALK inhibitors like alectinib, brigatinib, and lorlatinib have since improved on crizotinib’s results and can work even after crizotinib stops controlling the cancer.¹⁰

For years, one of the most common mutations in NSCLC, KRAS G12C, was considered undruggable. That changed in 2021 when sotorasib became the first approved treatment specifically designed to lock onto the KRAS G12C protein and shut down its growth signals.¹¹ Clinical trials showed that sotorasib produced meaningful tumor shrinkage and a durable response in a meaningful share of patients who had already been through other treatments.¹² Adagrasib, a second KRAS G12C inhibitor, followed shortly after.

Immunotherapy and the Role of PD-L1

Immune checkpoint inhibitors have become a cornerstone of NSCLC treatment, particularly for tumors that lack a clear targetable mutation. These drugs work by removing the brakes that cancer cells put on the immune system, allowing T cells to attack the tumor. The PD-1/PD-L1 pathway is the main target. When given as single agents after other treatments failed, these drugs improved overall survival compared to chemotherapy, with a pooled hazard ratio of about 0.77 across multiple trials.¹³

PD-L1 expression on tumor cells matters, but not in a simple on-or-off way. Patients with very high PD-L1 expression get the most striking benefit: in one real-world study, those with very high PD-L1 levels who received immunotherapy had a median survival of nearly four years, compared to about a year and a half for those with lower expression.¹⁴ But even tumors with no detectable PD-L1 can respond, especially when immunotherapy is combined with chemotherapy. A large meta-analysis of PD-L1-negative NSCLC found that immunotherapy combined with chemotherapy achieved response rates around 48 percent and a median overall survival of nearly 16 months.¹⁵ That finding is why chemo-immunotherapy combinations have become standard first-line treatment for most advanced NSCLC patients who do not have an actionable mutation.

Beyond PD-L1, researchers have been investigating tumor mutational burden (TMB) as another way to predict who will respond to immunotherapy. The idea is straightforward: tumors with more mutations produce more abnormal proteins on their surface, giving the immune system more targets to recognize. Lung cancer tends to have a high mutation rate, which partly explains why it responds to checkpoint inhibitors better than many other cancer types.¹⁶ In practice, TMB has proven useful but imperfect as a standalone predictor, and it is not yet routinely used to make treatment decisions in the way PD-L1 staining is.

Surgery for Early-Stage Disease

When NSCLC is caught at an early stage and the tumor has not spread to distant sites, surgery offers the best chance of cure. Lobectomy, removing the entire lobe of the lung containing the tumor, has long been the gold standard. But for smaller tumors, particularly those under two centimeters, a more limited operation called segmentectomy has gained ground. It removes a smaller wedge of lung tissue and preserves more breathing capacity.

A recent meta-analysis comparing the two approaches in early-stage NSCLC found no significant difference in overall survival, disease-free survival, or recurrence-free survival between segmentectomy and lobectomy.¹⁷ An earlier study suggested lobectomy had a survival edge in stage I disease overall, but segmentectomy performed equally well for stage IA tumors specifically, the smallest and most localized cancers.¹⁸ Segmentectomy is particularly attractive for patients whose lung function is already compromised and who might not tolerate removing an entire lobe.¹⁹

For patients with early-stage disease who cannot have surgery at all, stereotactic body radiation therapy (SBRT) has emerged as a powerful alternative. SBRT delivers very high doses of precisely focused radiation in just a few sessions. Phase II trials in medically inoperable patients reported local tumor control rates above 90 percent at three years, with limited side effects.²⁰ Some centers have adopted single-fraction SBRT, delivering the entire dose in one session, with outcomes comparable to multi-session schedules.²¹ Longer follow-up studies show median overall survival around four years and a five-year survival rate of about 40 percent in patients who were deemed too sick for surgery.²²

Immunotherapy Before and After Surgery

An exciting development in recent years is the use of immunotherapy around the time of surgery, rather than reserving it for advanced disease. Giving checkpoint inhibitors before an operation (neoadjuvant therapy), after it (adjuvant therapy), or both can help eliminate microscopic cancer cells that imaging cannot detect. Several large randomized trials have shown that combining neoadjuvant chemotherapy with immunotherapy improves pathologic complete response rates, meaning more patients have no viable cancer left in the surgical specimen, along with improved survival outcomes and no major increase in surgical complications.²³ These results have led to updates in international treatment guidelines for resectable stage IB through IIIA NSCLC.

When Treatments Stop Working

Drug resistance is the central frustration in treating advanced NSCLC. Nearly every patient on a targeted therapy will eventually see their cancer adapt and start growing again. For EGFR-targeted drugs, the most common escape route is a secondary mutation called T790M, which shows up in about half of cases. This mutation changes the shape of the protein enough that earlier drugs can no longer bind effectively.²⁴ Another 5 to 20 percent of resistant cases involve amplification of a different gene called MET, which activates a parallel growth pathway the tumor can rely on instead.²⁵ Interestingly, these two mechanisms tend to be mutually exclusive. In one study of tumors that had stopped responding to gefitinib, T790M was found in 93 percent of tumors without MET amplification, but in only 8 percent of tumors with high-level MET amplification.²⁶ Osimertinib was specifically designed to overcome T790M resistance, but eventually tumors find yet another workaround, creating a cycle that researchers are still working to break.

Resistance to immunotherapy is a separate and arguably harder problem. Unlike targeted therapy, where resistance often traces to a single identifiable mutation, immunotherapy resistance is driven by a wide variety of mechanisms. The tumor can change its surface proteins, alter the surrounding immune environment, or activate entirely different suppressive pathways. Most patients who progress on checkpoint inhibitors currently have limited options. The standard second-line treatment, docetaxel, produces a response rate of only about 10 percent, and newer immunotherapy agents tested in this setting have not beaten that benchmark.²⁷ A big part of the problem is that resistance is heterogeneous: two patients whose cancers progressed on the same drug may have completely different biological reasons for it, making one-size-fits-all approaches ineffective.

Antibody-Drug Conjugates and Emerging Treatments

Antibody-drug conjugates (ADCs) represent one of the more promising new drug classes for NSCLC. These are engineered molecules that combine an antibody, which seeks out a specific protein on the cancer cell, with a potent chemotherapy payload. The antibody delivers the drug directly to the tumor, limiting damage to healthy tissue. One target getting particular attention is TROP2, a protein broadly expressed on NSCLC cells. Datopotamab deruxtecan (Dato-DXd), a TROP2-directed ADC, showed improved progression-free survival compared to standard chemotherapy in previously treated NSCLC in a large phase III trial, though overall survival did not significantly differ. The benefit was concentrated in nonsquamous NSCLC, where median progression-free survival was 5.5 months versus 3.6 months with standard chemotherapy. By contrast, patients with squamous cell tumors saw no benefit, likely because squamous tumors are less reliant on TROP2 signaling.²⁸ This kind of histology-dependent response is a reminder that even within NSCLC, the subtypes behave as distinct diseases.

Artificial intelligence is also beginning to reshape how NSCLC is diagnosed and managed. AI models can now perform rapid tumor subtyping on digital pathology slides and extract features from CT and PET scans that are invisible to the human eye, helping to map tumor characteristics and metastatic risk without an invasive biopsy.²⁹ These tools are not replacing oncologists, but they are accelerating the diagnostic pipeline and may eventually help match patients to therapies more precisely.

Early Palliative Care Changes Outcomes

One of the most counterintuitive findings in NSCLC research involves palliative care. Many people equate palliative care with end-of-life care, but that misses what it actually is: specialized attention to symptoms, side effects, emotional distress, and overall quality of life, delivered alongside active cancer treatment. A landmark trial at Massachusetts General Hospital randomized patients with metastatic NSCLC to receive either standard oncology care or standard care plus early palliative care from the time of diagnosis. The palliative care group had better quality of life, lower rates of depression (16 percent versus 38 percent), and received less aggressive end-of-life interventions. The striking result: they also lived longer, with a median survival of 11.6 months compared to 8.9 months.³⁰

These findings have been replicated in other settings. A trial in China found that early palliative care similarly improved quality of life, reduced depressive symptoms, and led to better nutritional status.³¹ Additional research has confirmed improvements in mood and lung function as well.³² The mechanism is not fully understood, but the prevailing explanation is that better symptom control allows patients to stay on treatment longer, maintain physical function, and avoid the harms of overly aggressive care that does more damage than good.

The Financial Side of NSCLC Treatment

Modern NSCLC treatment has become dramatically more effective, but it has also become dramatically more expensive. Targeted therapies and immunotherapy drugs can cost tens of thousands of dollars per month. Even patients with insurance often face substantial out-of-pocket costs through copays and coinsurance. This financial burden is not a minor inconvenience: rising cost-sharing has been linked to worse quality of life, greater psychological distress, and poorer treatment adherence, meaning some patients skip doses or delay refills because they cannot afford them.³³ Oncologists increasingly recognize “financial toxicity” as a legitimate side effect of cancer treatment, and many cancer centers now employ financial counselors or social workers to help patients navigate assistance programs. The tension between the remarkable clinical progress in NSCLC and the economic barriers to accessing that progress remains one of the disease’s defining challenges.

1
PubMed Central. Familial risk for lung cancer ↩︎
2
PubMed. Differences in epidemiology, histology, and survival between cigarette smokers and never-smokers who develop non-small cell lung cancer ↩︎
3
European Respiratory Review. Lung cancer is also a hereditary disease ↩︎
4
PubMed. Reduced Lung-Cancer Mortality with Low-Dose Computed Tomographic Screening ↩︎
5
PubMed. Reduced Lung-Cancer Mortality with Volume CT Screening in a Randomized Trial ↩︎
6
PubMed Central. Low‐dose computed tomography lung cancer screening: Clinical evidence and implementation research ↩︎
7
PubMed Central. EGFR-Targeted Therapies: A Literature Review ↩︎
8
PubMed. Navigating First-Line Treatment Options for Patients With Epidermal Growth Factor Receptor-Positive Non-Small Cell Lung Cancer ↩︎
9
PubMed. Targeted therapies in non-small cell lung cancer: a focus on ALK/ROS1 tyrosine kinase inhibitors ↩︎
10
PubMed Central. ALK and ROS1 as targeted therapy paradigms and clinical implications to overcome crizotinib resistance ↩︎
11
PubMed Central. Targeted therapies for KRAS-mutant non-small cell lung cancer: from preclinical studies to clinical development—a narrative review ↩︎
12
PubMed Central. Sotorasib: A Review in KRAS G12C Mutation-Positive Non-small Cell Lung Cancer ↩︎
13
PubMed Central. The association of PD-L1 expression with the efficacy of anti-PD-1/PD-L1 immunotherapy and survival of non-small cell lung cancer patients: a meta-analysis of randomized controlled trials ↩︎
14
PubMed Central. Very High PD-L1 Expression as a Prognostic Indicator of Overall Survival among Patients with Advanced Non-Small Cell Lung Cancer receiving Anti PD-(L)1 Monotherapies in Routine Practice ↩︎
15
PubMed. Efficacy of immune checkpoint inhibitors (ICIs) in PD-L1 negative Non-Small Cell Lung Cancer (NSCLC) – A meta-analysis based on reconstructed individual participant data ↩︎
16
PubMed Central. Clinical utility of tumor mutational burden in patients with non-small cell lung cancer treated with immunotherapy ↩︎
17
PubMed Central. Survival outcomes of segmentectomy and lobectomy for early stage non-small cell lung cancer: a systematic review and meta-analysis ↩︎
18
PubMed. Comparison of the oncologic outcomes of anatomic segmentectomy and lobectomy for early-stage non-small cell lung cancer ↩︎
19
PubMed Central. Segmentectomy versus lobectomy. Which factors are decisive for an optimal oncological outcome? ↩︎
20
PubMed. Outcome in a prospective phase II trial of medically inoperable stage I non-small-cell lung cancer patients treated with stereotactic body radiotherapy ↩︎
21
PubMed. Ten-Year Experience in Implementing Single-Fraction Lung SBRT for Medically Inoperable Early-Stage Lung Cancer ↩︎
22
International Journal of Radiation Oncology, Biology, Physics. Long-Term Results of a Prospective Phase II Trial of Stereotactic Body Radiation Therapy for Medically Inoperable Stage I Non-Small Cell Lung Cancer ↩︎
23
PubMed. Neoadjuvant immunotherapy strategies for resectable non-small cell lung cancer (NSCLC): Current evidence among special populations and future perspectives ↩︎
24
PubMed. EGFR T790M mutation: a double role in lung cancer cell survival? ↩︎
25
PubMed Central. Mechanisms of resistance to EGFR-targeted drugs: lung cancer ↩︎
26
Clinical Cancer Research. Reciprocal and Complementary Role of MET Amplification and EGFR T790M Mutation in Acquired Resistance to Kinase Inhibitors in Lung Cancer ↩︎
27
Journal for ImmunoTherapy of Cancer. Categorizing immunotherapy resistance mechanisms in non-small cell lung cancer: how can we perform better? ↩︎
28
PubMed Central. Antibody drugs conjugates in non–small cell lung cancer: current status and challenges ↩︎
29
PubMed Central. Artificial intelligence in non-small cell lung cancer: transforming diagnosis, treatment, and prognostic evaluation ↩︎
30
PubMed. Early Palliative Care for Patients with Metastatic Non-Small-Cell Lung Cancer ↩︎
31
PubMed. Early Palliative Care in Patients With Non-Small-Cell Lung Cancer: A Randomized Controlled Trial in Southwest China ↩︎
32
PubMed Central. Effect of early palliative care on quality of life in patients with non-small-cell lung cancer ↩︎
33
PubMed Central. Financial toxicity and implications for cancer care in the era of molecular and immune therapies ↩︎